chemotherapy - search results

Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University sheds light on dose-finding trials

Ivan Stamenkovic, professor of experimental pathology at the University of Lausanne underlines research taking place around cancer progression Cancer progression, meaning the evolution of localised tumour growth to an invasion of adjacent tissue and dissemination to distant organs is a complex process that is intimately related to interactions between tumour...

Targeted stem cell research at the University of California, Irvine could one day eradicate glioblastoma brain tumours, explains John Lowengrub

Professor Jatinder Lamba from the Department of Pharmacotherapy and Translational Research explores the current progress in Acute Myeloid Leukaemia (AML)

David Partridge from the British Infection Association provides a comprehensive overview of effective infection prevention and control in the UK today

After extended campaigns from charities and prominent figures, a lung cancer drug said to extend the life of sufferers has been made available on the NHS The nivolumab lung cancer drug is already available in Scotland for those with advanced lung cancer who are already undergoing chemotherapy. The immunotherapy treatment stimulates...

Biomedical research crosses borders of disciplines to help shape new imaging approaches, as scientists from Technical University of Munich explain

John Lowengrub and colleagues provide insight into the challenge to eradicate glioblastoma and the use of stem cell transdifferentiation.   Huaming Yan1,7, Mónica Romero-López2, Lesly I. Benitez4, Kaijun Di4,9, Hermann B. Frieboes5,6, Christopher C. W. Hughes2,4,7,8, Daniela A. Bota8,9,10, Vittorio Cristini11, John Lowengrub1,2,7,8 1 Dept. of Mathematics, University of California, Irvine, CA 92697 2 Dept....

Photodynamic Therapy is a treatment that combines a photosensitizing drug, visible light and oxygen to kill cancer cells. Professor Eli Glatstein explains

Sumith A Kularatne, Vice President of Research & Development at On Target Laboratories discusses the scope of image-guided surgery in treating lung cancer

The European Federation of Pharmaceutical Industries and Associations (EFPIA) explain how SAFE-T DIKI is advancing research into drug-induced kidney injury

Can we prevent the muscle loss associated with some cancers? Dr Vera Mazurak at the University of Alberta is looking into one method of treating myosteatosis Pathological fat infiltration into muscle is a feature of disease-induced muscle loss that significantly associates with shorter survival in people with cancer. Fat is...

Open Access Government spoke to the National Cancer Institute’s Dr S Percy Ivy about cancer research and training and the importance of clinical trials The National Cancer Institute (NCI) is one of 27 institutes that make up the National Institutes of Health (NIH). The NCI is the US federal government’s...

New avenues are opening up for treatment of gynaecological cancer, Professor Gunnar Kristensen of Oslo University Hospital explains to Open Access Government Surgery remains an important step in the treatment of ovarian cancer. Two earlier randomised studies revealed the same survival rates for patients who had surgery as the first...

Dr Sumith A Kularatne, vice-president of R&D at On Target Laboratories, explores the pros and cons of various existing treatments for prostate cancer Prostate cancer (PCa) is the second leading cause of cancer-related deaths in men, with about 1.1 million new cases and approximately 307,000 fatalities per year globally. This...

The Orkdal model of cancer care rests on collaboration between specialist oncology and community care in palliative treatment, as Anne Kari Knudsen explains The Norwegian Orkdal model of cancer care has been called “the future of cancer care”. The aim is to develop and implement a model for optimal cancer...

Gunnar Kristensen, from the Department of Gynaecologic Oncology at Oslo University Hospital, looks at new strategies for the treatment of ovarian cancer. It is recognised that the disease we usually call ovarian cancer can originate from either the ovaries, the fallopian tube (the organ bringing the eggs from the ovaries...

Zhihui Wang1,2 and Vittorio Cristini1,2   outline how they have developed a model to help predict cancer treatment outcomes… The physical properties of a tumour’s microenvironment influence a drug’s ability to penetrate and kill tumour cells. Some of these properties can be potential obstructions to drug diffusion, increasing the tumour’s resistance...

Professor Alan Johnson, Head of the Department of Healthcare-Associated Infection and Antimicrobial Resistance at Public Health England, explains to Editor Laura Evans about healthcare association infections and how they link to antibiotic resistance Healthcare-Associated Infections (HCAIs) are infections that are contracted within healthcare settings, such as hospitals and care homes. They...

Cancer is a complex and heterogeneous disease. Despite all efforts to fight cancer, it continues to impact every segment of society. For example, many patients fail conventional cancer therapies, including chemotherapy, radiation, and surgery; and it is still difficult for physicians to predict a treatment outcome with certainty.